Don't miss the most important voices in pharma
Let PharmaVoice's free newsletter keep you informed on what industry leaders are saying, straight from your inbox.
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.
AbbVie headquarters in San Francisco, Calif., on July 31, 2021.
This audio is auto-generated. Please let us know if you have
Botox has been synonymous with aesthetics for decades, even achieving the elusive and sometimes frustrating status of being shorthand for an entire category of products.
weren’t aimed at reducing wrinkles. Instead, they targeted two rare eye muscle disorders, showcasing the potential of the neurotoxin in therapeutic indications.
“Since then, in the U.S., we have [won approval for] over 15 indications, and that includes aesthetics and therapeutic indications collectively,” said Emily Barry, vice president, head of toxin office strategy and advancement at AbbVie.
Botox’s regulatory wins have included nods in overactive bladder, migraine headaches and muscle stiffness in patients with limb spasticity. Now, AbbVie is drawing on that history to advance the science more broadly around neurotoxins and expand its pipeline with two new candidates, while seeking new therapeutic indications for Botox as well.
“We’re investing in what we call next-generation capabilities,” Barry said. “That will allow us to set ourselves up for success to meet the needs for both aesthetics and therapeutics, but also ensure we’re meeting those key components around quality, reliability and scalability for the future of the pipeline.”
AbbVie’s “next-generation toxin” AGN-151607 is advancing into clinical trials next year for
“Those are indications that have really high unmet need. There are no toxins currently available in those areas,” Barry said.
the drug, which is a type of botulinum toxin type A, to prevent postoperative atrial fibrillation,
after its endpoints weren’t met.
in October that it hit its primary endpoint in a phase 2 trial evaluating the safety and efficacy of Botox compared to placebo in treating upper limb essential tremor.
The positive results buoyed AbbVie’s outlook for using neurotoxins, including AGN-151607, to treat the condition, which can impact hands and arms, and take a toll on patients’ daily life.
“Based on that, we have the confidence to take our next-generation toxin into development with [essential tremor],” Barry said.
AGN-151607 also builds on AbbVie’s broader movement disorder portfolio, which includes Vyalev, a 24-hour infusion to treat motor fluctuations in adults with advanced Parkinson's disease that
in the same indication. Its next hopeful in the space, an oral drug called tavapadon, was submitted
to treat Parkinson’s in September.
“If you look at that foundation we’ve established in movement disorders, and if you look at the foundation that’s been established with Botox, also in movement disorders in conditions like spasticity … we are excited about the opportunity to now go into a new portion of movement disorders,” Barry said.
Reclaiming the aesthetics market
At the same time, AbbVie is expanding its aesthetics offerings in the neurotoxins market. The company submitted an application to the FDA
for TrenibotE to treat glabellar lines, aiming to offer patients a neurotoxin injection that works more quickly and wears off faster than Botox.
“You can imagine someone who wants to maybe experiment before they commit to what we call a classic-duration toxin like Botox, that's what TrenibotE will enable,” Barry said. “They can go into the clinic, get it administered, start to see an effect within a day, and then they can determine whether they want to go in for more.”
TrenibotE will also help Botox against competitors in the aesthetic neurotoxin space, including the newest entrant, Letybo, known as “Korean Botox,” which got the
In addition, Barry said TrenibotE will be “specifically for aesthetics,” like another Botox rival, Jeuveau, whereas other competitors like Merz Pharmaceuticals’ Xeomin, also have therapeutic indications.
Despite claiming a market share hovering above
, Botox has faced struggles recently.
from AbbVie’s aesthetics portfolio, which also includes Juvéderm, were down 3.7% on a reported basis compared to third quarter 2024. Allergan, AbbVie’s aesthetics division
roughly 200 employees over the summer after launching, then scrapping, a rewards program for Botox called Allē that fell flat with consumers.
“When you look at our share, what we can see is that year over year, we are lower than we were last year because of the Allē reimagined,” Jeffrey Stewart, AbbVie’s executive vice president and chief commercial officer, said during the company’s
But AbbVie is aiming to get a stronger foothold in the market with a new Botox marketing campaign that launched in September, while leaning into its broader neurotoxin R&D to set the stage for future growth.
“We're emerging into the next stage, the next wave around toxins,” Barry said.
Will 2026 be pharma’s M&A breakout year?
AbbVie dives back into the neuro pool with a .2B psychedelics play
PharmaVoice stories and insights delivered to your inbox
Get the free daily newsletter read by industry leaders
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
The leading GLP-1 contenders in pharma’s race for an obesity pill
Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape.
Keep up with the story. Subscribe to the PharmaVoice free daily newsletter
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
Subscribe to PharmaVoice for important stories, insights & perspectives
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
The leading GLP-1 contenders in pharma’s race for an obesity pill
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
Biopharma CEO optimism is wavering in the US
After years of debate, the Biosecure Act could be headed for Trump’s desk
The Evolution of Outsourced Buffer Production in Manufacturing
How to Unlock A Successful ICH E6(R3) Implementation
Successful Biomarker-Driven Cancer Drug Development
PharmaVoice stories and insights delivered to your inbox
Get the free daily newsletter read by industry leaders
By signing up to receive our newsletter, you agree to our
. You can unsubscribe at anytime.
A valid email address is required.
Please select at least one newsletter.
Infectious Diseases Specialist Serves on the Editorial Board of MerckManuals.com
OPEN Health Welcomes Diala Habib to Drive a New Era of Human-Centric Engagement Connecting HCP…
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity
Renowned Endocrinologist Glenn D. Braunstein, MD, Serves on the Editorial Board of MerckManual…
The leading GLP-1 contenders in pharma’s race for an obesity pill
Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape.
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
Biopharma CEO optimism is wavering in the US
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Industry Dive is an Informa TechTarget business.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. | View our
Cookie Preferences / Do Not Sell
This website is owned and operated by Informa TechTarget, part of a global network that informs, influences